Plasma and tissue concentrations of proangiotensin-12 in rats treated with inhibitors of the renin-angiotensin system

Hypertension Research

Volumn 35, Issue 2, 2012, Pages 234-238

  Nagata, Sayaka ^a   Kato, Johji ^b   Kuwasako, Kenji ^b   Asami, Maki ^a   Kitamura, Kazuo ^a  

^a UNIVERSITY OF MIYAZAKI   (Japan)

^b UNIVERSITY OF MIYAZAKI   (Japan)

Author keywords

ACE inhibitor; angiotensin; angiotensin receptor blocker; proangiotensin 12; renin

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN II; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMIDAPRIL; LOSARTAN; PROANGIOTENSIN 12; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; ESSENTIAL HYPERTENSION; MALE; NONHUMAN; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTEMIC CIRCULATION;

ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANGIOTENSINOGEN; ANIMALS; BLOOD PRESSURE; BODY WEIGHT; IMIDAZOLIDINES; KIDNEY; LOSARTAN; MALE; MYOCARDIUM; ORGAN SIZE; PEPTIDE FRAGMENTS; RADIOIMMUNOASSAY; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 84856746787     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2011.165     Document Type: Article

References (32)

1. Oparil S, Haber E. The renin-angiotensin system (first of two parts). NEngl JMed 1974; 291: 389-401.
2. Dzau VJ. Significance of the vascular renin-angiotensin pathway. Hypertension 1986; 8: 553-559. (Pubitemid 16066758)
3. Dzau VJ, Burt DW, Pratt RE. Molecular biology of the renin-angiotensin system. Am J Physiol 1988; 255(4 Pt 2): F563-F573.
4. Campbell DJ. Circulating and tissue angiotensin systems. J Clin Invest 1987; 79: 1-6. (Pubitemid 17232490)
5. Fischer-Ferraro C, Nahmod VE, Goldstein DJ, Finkielman S. Angiotensin and renin in rat and dog brain. J Exp Med 1971; 133: 353-361.
6. Miyazaki M, Okunishi H, Okamura T, Toda N. Elevated vascular angiotensin converting enzyme in chronic two-kidney, one clip hypertension in the dog. J Hypertens 1987; 5: 155-160.
7. Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev 2006; 86: 747-803. (Pubitemid 44033382)
8. Nagata S, Kato J, Sasaki K, Minamino N, Eto T, Kitamura K. Isolation and identification of proangiotensin-12, a possible component of the renin-angiotensin system. Biochem Biophys Res Commun 2006; 350: 1026-1031. (Pubitemid 44596223)
9. Varagic J, Trask AJ, Jessup JA, Chappell MC, Ferrario CM. New angiotensins. J MolMed 2008; 86: 663-671.
10. Cummins PM. A new addition to the renin-angiotensin peptide family: proAngiotensin-(PA12). Cardiovasc Res 2009; 82: 7-8.
11. Prosser HC, Forster ME, Richards AM, Pemberton CJ. Cardiac chymase converts rat proAngiotensin-12 (PA12) to angiotensin II: effects of PA12 upon cardiac haemodynamics. Cardiovasc Res 2009; 82: 40-50.
12. Prosser HC, Richards AM, Forster ME, Pemberton CJ. Regional vascular response to ProAngiotensin-12 (PA12) through the rat arterial system. Peptides 2010; 31: 1540-1545.
13. Ahmad S, Varagic J, Westwood BM, Chappell MC, Ferrario CM. Uptake and metabolism of the novel Peptide Angiotensin-(1-12) by neonatal cardiac myocytes. PLoS ONE 2011; 6: e15759.
14. Trask AJ, Jessup JA, Chappell MC, Ferrario CM. Angiotensin-(1-12) is an alternate substrate for angiotensin peptide production in the heart. Am J Physiol Heart Circ Physiol 2008; 294: H2242-H2247.
15. Bujak-Gizycka B, Olszanecki R, Suski M, Madek J, Stachowicz A, Korbut R. Angiotensinogen metabolism in rat aorta: robust formation of proangiotensin-12. J Physiol Pharmacol 2010; 61: 679-682.
16. Jessup JA, Trask AJ, Chappell MC, Nagata S, Kato J, Kitamura K, Ferrario CM. Localization of the novel angiotensin peptide, angiotensin-(1-12), in heart and kidney of hypertensive and normotensive rats. Am J Physiol Heart Circ Physiol 2008; 294: H2614-H2618.
17. Ferrario CM, Varagic J, Habibi J, Nagata S, Kato J, Chappell MC, Trask AJ, Kitamura K, Whaley-Connell A, Sowers JR. Differential regulation of angiotensin-(1-12) in plasma and cardiac tissue in response to bilateral nephrectomy. Am J Physiol Heart Circ Physiol 2009; 296: H1184-H1192.
18. Nagata S, Kato J, Kuwasako K, Kitamura K. Plasma and tissue levels of proangiotensin-and components of the renin-angiotensin system (RAS) following low-or high-salt feeding in rats. Peptides 2010; 31: 889-892.
19. Dai Q, Xu M, Yao M, Sun B. Angiotensin AT1 receptor antagonists exert antiinflammatory effects in spontaneously hypertensive rats. Br J Pharmacol 2007; 152: 1042-1048. (Pubitemid 350166045)
20. Katoh M, Egashira K, Kataoka C, Usui M, Koyanagi M, Kitamoto S, Ohmachi Y, Takeshita A, Narita H. Regression by ACE inhibition of arteriosclerotic changes induced by chronic blockade of NO synthesis in rats. Am J Physiol Heart Circ Physiol 2001; 280: H2306-H2312.
21. Kobori H, Katsurada A, Miyata K, Ohashi N, Satou R, Saito T, Hagiwara Y, Miyashita K, Navar LG. Determination of plasma and urinary angiotensinogen levels in rodents by newly developed ELISA. Am J Physiol Renal Physiol 2008; 294: F1257-F1263.
22. Katsurada A, Hagiwara Y, Miyashita K, Satou R, Miyata K, Ohashi N, Navar LG, Kobori H. Novel sandwich ELISA for human angiotensinogen. Am J Physiol Renal Physiol 2007; 293: F956-F960. (Pubitemid 47403368)
23. Inagami T, Misono K, Michelakis AM. Definitive evidence for similarity in the active site of renin and acidic protease. Biochem Biophys Res Commun 1974; 56: 503-509.
24. Wagner J, Drab M, Bohlender J, Amann K, Wienen W, Ganten D. Effects of AT1 receptor blockade on blood pressure and the renin-angiotensin system in spontaneously hypertensive rats of the stroke prone strain. Clin Exp Hypertens 1998; 20: 205-221. (Pubitemid 28160942)
25. Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, Diz DI, Gallagher PE. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 2005; 111: 2605-2610. (Pubitemid 40740859)
26. Agata J, Ura N, Yoshida H, Shinshi Y, Sasaki H, Hyakkoku M, Taniguchi S, Shimamoto K. Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme. Hypertens Res 2006; 29: 865-874. (Pubitemid 46062117)
27. Wei CC, Hase N, Inoue Y, Bradley EW, Yahiro E, Li M, Naqvi N, Powell PC, Shi K, Takahashi Y, Saku K, Urata H, Dell¢italia LJ, Husain A. Mast cell chymase limits the cardiac efficacy of Ang I-converting enzyme inhibitor therapy in rodents. J Clin Invest 2010; 120: 1229-1239.
28. Mento PF, Wilkes BM. Plasma angiotensins and blood pressure during converting enzyme inhibition. Hypertension 1987; 9(6 Pt 2): III42-III48.
29. Koji T, Onishi K, Dohi K, Okamoto R, Tanabe M, Kitamura T, Ito M, Isaka N, Nobori T, Nakano T. Addition of angiotensin II receptor antagonist to an ACE inhibitor in heart failure improves cardiovascular function by a bradykinin-mediated mechanism. J Cardiovasc Pharmacol 2003; 41: 632-639. (Pubitemid 36373802)
30. Matsumoto N, Ishimitsu T, Okamura A, Seta H, Takahashi M, Matsuoka H. Effects of imidapril on left ventricular mass in chronic hemodialysis patients. Hypertens Res 2006; 29: 253-260. (Pubitemid 43853271)
31. Nagano M, Higaki J, Mikami H, Nakamaru M, Higashimori K, Katahira K, Tabuchi Y, Moriguchi A, Nakamura F, Ogihara T. Converting enzyme inhibitors regressed cardiac hypertrophy and reduced tissue angiotensin II in spontaneously hypertensive rats. J Hypertens 1991; 9: 595-599.
32. Aihara E, Kagawa S, Hayashi M, Takeuchi K. ACE inhibitor and AT1 antagonist stimulate duodenal HCO3-secretion mediated by a common pathway-involvement of PG, NO and bradykinin. J Physiol Pharmacol 2005; 56: 391-406. (Pubitemid 41406473)